Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Beta Selective Thyroid Hormone Receptor Agonist: Overview
Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. A lack of thyroid hormones is not compatible with normal health. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TR? and TR?, with the TR? isoform known to be responsible for the main beneficial effects of TH on liver. In brain, despite the crucial role of TR? isoform in neuronal development, TR? has been proposed to play a role in the remyelination processes. TR? is the predominant isoform of TR in the liver and therefore is primarily responsible for the reduction of cholesterol levels, whereas the adverse effects on heart and bone are mainly connected to TR?. Thus, in the development of clinically useful drug candidates, much effort has been directed toward the design of compounds with isomer-specific activity related to the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TR? selective.
'Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape is provided which includes the disease overview and Beta Selective Thyroid Hormone Receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth Beta Selective Thyroid Hormone Receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta Selective Thyroid Hormone Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Beta Selective Thyroid Hormone Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs
Further product details are provided in the report……..
Beta Selective Thyroid Hormone Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Beta Selective Thyroid Hormone Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Beta Selective Thyroid Hormone Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta Selective Thyroid Hormone Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta Selective Thyroid Hormone Receptor Agonist drugs.
Beta Selective Thyroid Hormone Receptor Agonist Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Beta Selective Thyroid Hormone Receptor Agonist: Overview
Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. A lack of thyroid hormones is not compatible with normal health. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TR? and TR?, with the TR? isoform known to be responsible for the main beneficial effects of TH on liver. In brain, despite the crucial role of TR? isoform in neuronal development, TR? has been proposed to play a role in the remyelination processes. TR? is the predominant isoform of TR in the liver and therefore is primarily responsible for the reduction of cholesterol levels, whereas the adverse effects on heart and bone are mainly connected to TR?. Thus, in the development of clinically useful drug candidates, much effort has been directed toward the design of compounds with isomer-specific activity related to the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TR? selective.
'Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape is provided which includes the disease overview and Beta Selective Thyroid Hormone Receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth Beta Selective Thyroid Hormone Receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta Selective Thyroid Hormone Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Beta Selective Thyroid Hormone Receptor Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Beta Selective Thyroid Hormone Receptor Agonist.
This segment of the Beta Selective Thyroid Hormone Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs
- Resmetirom: Madrigal Pharmaceuticals
- VK2809: Viking Therapeutics
Further product details are provided in the report……..
Beta Selective Thyroid Hormone Receptor Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Beta Selective Thyroid Hormone Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Beta Selective Thyroid Hormone Receptor Agonist
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Beta Selective Thyroid Hormone Receptor Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta Selective Thyroid Hormone Receptor Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta Selective Thyroid Hormone Receptor Agonist drugs.
Beta Selective Thyroid Hormone Receptor Agonist Report Insights
- Beta Selective Thyroid Hormone Receptor Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Beta Selective Thyroid Hormone Receptor Agonist drugs?
- How many Beta Selective Thyroid Hormone Receptor Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta Selective Thyroid Hormone Receptor Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta Selective Thyroid Hormone Receptor Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Beta Selective Thyroid Hormone Receptor Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Madrigal Pharmaceuticals
- Ascletis
- Eccogene
- Viking Therapeutics
- Aligos Therapeutics
- Autobahn Therapeutics
- Terns Pharmaceuticals
- Viking Therapeutics
- Resmetirom
- ASC-41
- Research programme: thyroid hormone receptor beta agonists
- VK2809
- ALG-055009
- ABX-002
- TERN-501
- VK 0214
Introduction
Executive Summary
Beta Selective Thyroid Hormone Receptor Agonist: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
VK2809: Viking Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
ASC-41: Ascletis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
ALG-055009: Aligos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Beta Selective Thyroid Hormone Receptor Agonist Key Companies
Beta Selective Thyroid Hormone Receptor Agonist Key Products
Beta Selective Thyroid Hormone Receptor Agonist- Unmet Needs
Beta Selective Thyroid Hormone Receptor Agonist- Market Drivers and Barriers
Appendix
Executive Summary
Beta Selective Thyroid Hormone Receptor Agonist: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
VK2809: Viking Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
ASC-41: Ascletis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
ALG-055009: Aligos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Beta Selective Thyroid Hormone Receptor Agonist Key Companies
Beta Selective Thyroid Hormone Receptor Agonist Key Products
Beta Selective Thyroid Hormone Receptor Agonist- Unmet Needs
Beta Selective Thyroid Hormone Receptor Agonist- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Beta Selective Thyroid Hormone Receptor Agonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
